// App-Quantinova.ai

OT1-08-04 : A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Researchers

Presenter

  • Dejan Juric

Principal Investigators

  • Mafalda Oliveira

  • Andres Cervantes

  • Philippe Bedard

  • Ian Krop

  • Erika Hamilton

  • Peter Schmid

  • Andrea Varga

  • Nick Turner

  • Antoine Italiano

  • Cristina Saura

  • Valentina Gambardella

  • Zachary Veitch

  • Leslie Dickmann

  • Naoki Kotani

  • Jill Fredrickson

  • Amy Kapp

  • Katie Hutchinson

  • Stephanie Royer-Joo

  • Anjali Vaze

  • Jennifer Schutzman

  • Komal Jhaveri

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • Columbia University Medical Center, New York, NY

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • University of Valencia, Valencia, Spain

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Institute for Cancer Research, London, United Kingdom

  • Institut Bergonie, Bordeaux, France

  • Genentech, Inc., South San Francisico, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Spain

  • Canada

  • United Kingdom

  • France

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT03006172

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved